Seidner Douglas L, Lashner Bret A, Brzezinski Aaron, Banks Phillip L C, Goldblum John, Fiocchi Claudio, Katz Jeffry, Lichtenstein Gary R, Anton Peter A, Kam Lori Y, Garleb Keith A, Demichele Stephen J
Department of Gastroenterology\A30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Clin Gastroenterol Hepatol. 2005 Apr;3(4):358-69. doi: 10.1016/s1542-3565(04)00672-x.
BACKGROUND & AIMS: N-3 fatty acids from fish oil, antioxidants, and short-chain fatty acids (SCFAs) produced during the fermentation of soluble fiber may attenuate inflammation associated with ulcerative colitis (UC). We assessed the efficacy of a nutritionally balanced oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium on disease activity and medication use in adults with mild to moderate UC.
A total of 121 patients with UC and a disease activity index (DAI) from 3-9 on a 12-point scale were block randomized for extent of disease and smoking status. In addition to their usual diet, patients consumed 18 oz of the oral supplement or a carbohydrate-based placebo formula each day for 6 months. Clinical and histologic responses were assessed at 3 and 6 months or at the final visit. A change in average prednisone use between groups was tested by using a linear mixed-effects model.
Eighty-six patients completed the study. Baseline characteristics were not different between groups except for a higher total DAI score in the oral supplement group (7.3 +/- 1.3; n = 36) compared with the placebo group (6.2 +/- 2.0; n = 50) ( P < .05). Both groups showed significant and similar degree of improvement at 6 months in DAI (-2.5 for oral supplement and -2.8 for placebo) and histologic index (-1.9 for oral supplement vs. -2.0 for placebo). Both intent-to-treat and completed patients given oral supplement had a significantly greater rate of decrease in the dose of prednisone required to control clinical symptoms over 6 months as compared with the placebo group ( P < .001).
The improvement in clinical response combined with a decreased requirement for corticosteroids suggest that this enriched oral supplement can be a useful adjuvant therapy in patients with UC.
鱼油中的n-3脂肪酸、抗氧化剂以及可溶性纤维发酵过程中产生的短链脂肪酸(SCFAs)可能会减轻与溃疡性结肠炎(UC)相关的炎症。我们评估了一种富含鱼油、低聚果糖、阿拉伯胶、维生素E、维生素C和硒的营养均衡口服补充剂对轻至中度UC成年患者疾病活动度和药物使用情况的疗效。
总共121例UC患者,其疾病活动指数(DAI)在12分制中为3 - 9分,根据疾病范围和吸烟状况进行区组随机分组。除日常饮食外,患者每天服用18盎司口服补充剂或基于碳水化合物的安慰剂配方,持续6个月。在3个月和6个月或最后一次访视时评估临床和组织学反应。使用线性混合效应模型测试两组之间平均泼尼松使用量的变化。
86例患者完成了研究。除口服补充剂组的总DAI评分(7.3±1.3;n = 36)高于安慰剂组(6.2±2.0;n = 50)(P <.05)外,两组的基线特征无差异。两组在6个月时DAI(口服补充剂组为-2.5,安慰剂组为-2.8)和组织学指数(口服补充剂组为-1.9,安慰剂组为-2.0)均显示出显著且相似程度的改善。与安慰剂组相比,接受口服补充剂的意向性治疗患者和完成治疗患者在6个月内控制临床症状所需泼尼松剂量的降低率均显著更高(P <.001)。
临床反应的改善以及对皮质类固醇需求的降低表明,这种强化口服补充剂可作为UC患者有用的辅助治疗方法。